Generalized Anxiety Disorder (GAD) Market

1. Generalized Anxiety Disorder (GAD) Market Generalized Anxiety Disorder (GAD) is characterized by persistent and exaggerated anxiety and worry about everyday life events with no obvious reasons for worry. People with GAD may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with GAD find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. DelveInsight's "Generalized Anxiety Disorder - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Generalized Anxiety Disorder , historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Generalized Anxiety Disorder market report provides current treatment practices, emerging drugs, Generalized Anxiety Disorder market share of the individual therapies, current and forecasted Generalized Anxiety Disorder market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Generalized Anxiety Disorder treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2017-2030 View full report: https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad- market Generalized Anxiety Disorder Disease Understanding and Treatment Algorithm GAD is diagnosed when a person finds it difficult to control worry on more days than not for at least 6 months. An evaluation of symptom criteria, as outlined in DSM-V, is the first step for diagnosis followed by physical exam, blood tests, urine tests, gastric reflux tests, such as an X-ray of the digestive system or an endoscopy procedure to look at the esophagus, and stress tests. The DelveInsight Generalized Anxiety Disorder market report gives a thorough understanding of the Generalized Anxiety Disorder by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Generalized Anxiety Disorder Epidemiology The first nationally representative mental health survey, National Comorbidity Survey (NCS) fielded in 1990–1992 using the DSM-III-R diagnostic criteria and stratified persons aged 15–54 years in 48 US centers (NCS, n.d.). The lifetime prevalence of GAD was 5.7%, and the 12-month prevalence was 3.1%, wherein females were reported to be higher than males (Kessler et al., 1994). The Generalized Anxiety Disorder epidemiology division provide insights about historical and current Generalized Anxiety Disorder patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

2. Key Findings   Generalized Anxiety Disorder Drug Chapters The dynamics of the GAD market is anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&D activities. Companies like, BioHaven Pharmaceuticals (Troriluzole), Bionomics [BNC210], Fabre-Kramer Pharmaceuticals (Travivo), Sage Therapeutics (SAGE-217), VistaGen Therapeutics (PH94B), Forest Laboratories/ Allergan (Vilazodone), and others are investigating their candidates for GAD. Drug chapter segment of the Generalized Anxiety Disorder report encloses the detailed analysis of Generalized Anxiety Disorder marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Generalized Anxiety Disorder clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. Request for sample pages: https://www.delveinsight.com/sample-request/general-anxiety- disorder-gad-market Generalized Anxiety Disorder Market Outlook GAD is one of the most common mental disorders that is like the ship which has the power to direct all the tides, and how conveniently it can affect a person’s entire life ranging from personal to professional, the quality of life by disrupting the important activities of daily living, if not treated on time, Patients with GAD have symptoms of anxiety ranging from mild to debilitating. Clinicians need to determine who needs treatment. This decision depends on many factors, including symptom intensity and duration, impact on the patient’s ability to function in daily life, comorbid conditions such as depression, and medical conditions. Patients with mild anxiety and worry who do not meet the DSM-V criteria for GAD often benefit from supportive therapy and encouragement. For those who do meet the criteria, one of the specific interventions described is indicated. Severe symptoms (e.g., a GAD-7 score greater than 15 and causing significant functional impairment) may need more intense initial therapy. Similarly, the patient’s medication regimen should be assessed for its potential to cause anxiety symptoms and addressed, when possible. The Generalized Anxiety Disorder market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Generalized Anxiety Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Generalized Anxiety Disorder market in 7MM is expected to change in the study period 2017-2030. Download free sample pages: https://www.delveinsight.com/sample-request/general-anxiety- disorder-gad-market In 2017, the total 12-month prevalent population of GAD was found to be 516,535, in Germany. Spain accounted for the least number of prevalent cases, i.e., 445,364 cases in 2017